| Ticker Details |
Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals Inc is a biotechnology company. It is engaged in the research and development of small molecule drugs for infectious diseases. The Group uses its chemistry-driven approach & drug discovery capabilities to develop its products.
|
| IPO Date: |
March 21, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$392.92M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.89 | 2.28%
|
| Avg Daily Range (30 D): |
$0.33 | 2.38%
|
| Avg Daily Range (90 D): |
$0.33 | 2.42%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.2M |
| Avg Daily Volume (30 D): |
.15M |
| Avg Daily Volume (90 D): |
.23M |
| Trade Size |
| Avg Trade Size (Sh.): |
73 |
| Avg Trade Size (Sh.) (30 D): |
45 |
| Avg Trade Size (Sh.) (90 D): |
53 |
| Institutional Trades |
| Total Institutional Trades: |
2,633 |
| Avg Institutional Trade: |
$1.78M |
| Avg Institutional Trade (30 D): |
$.58M |
| Avg Institutional Trade (90 D): |
$1.27M |
| Avg Institutional Trade Volume: |
.04M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.91M |
| Avg Closing Trade (30 D): |
$.58M |
| Avg Closing Trade (90 D): |
$1.4M |
| Avg Closing Volume: |
39.28K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$-3.21
|
$-.42
|
|
|
Diluted EPS
|
$-3.21
|
$-.42
|
|
|
Revenue
|
$66.98M
|
$18.62M
|
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$-71.54M
|
$-11.94M
|
|
|
Operating Income / Loss
|
$-73.06M
|
$-11.25M
|
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$-47.52M
|
$5.14M
|
|
|
PE Ratio
|
|
|
|
|
|
|